Base de dados : LILACS
Pesquisa : 174781 [Identificador único]
Referências encontradas : 1 [refinar]
Mostrando: 1 .. 1   no formato [Detalhado]

página 1 de 1

  1 / 1 LILACS  
para imprimir
Id: lil-174781
Autor: Nogales Gaete, Jorge; Arriagada, Camilo.
Título: Tratamiento de la esclerosis múltiple con interferones / Treatment of multiple sclerosis with interferons
Fonte: Rev. méd. Chile;124(5):597-604, mayo 1996.
Idioma: es.
Resumo: Despite the important achievements in clinical and experimental aspects of demylinating diseases and multiple sclerosis (MS), its pathogenesis still remains unknown. The most commonly held view is that it is an autoimmune disease, related in some way to a viral infection, that occurs in genetically susceptible hosts. Based on this, many current treatments for MS are designed to modulate the immune response and the interferons are an example. Only beta interferon has a dose dependent efficacy in phase III clinical trials, as treatment for remitting-relapsing forms. It produces a reduction in exacerbation rates and in the burden of the disease, measured by Magnetic Resonance imaging. The clinical use of beta interferon, considering the cost and large tretament period, must be cautious, reserving it only for confirmed remitting-relapsing modalities of MS. There is no clear cut evidence that beta interferon is useful for chronic-progressive MS
Descritores: Esclerose Múltipla/tratamento farmacológico
Interferons/administração & dosagem
Interferon beta/farmacologia
Interferon gama/farmacologia
Limites: Humanos
Tipo de Publ: Revisão
Responsável: CL1.1 - Biblioteca Central

página 1 de 1

Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  

Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde